Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma.

MLA

Knutson, Sarah K., et al. “Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma.” Molecular Cancer Therapeutics, vol. 13, no. 4, Apr. 2014, pp. 842–54. EBSCOhost, https://doi.org/10.1158/1535-7163.MCT-13-0773.

APA

Knutson, S. K., Kawano, S., Minoshima, Y., Warholic, N. M., Huang, K.-C., Xiao, Y., Kadowaki, T., Uesugi, M., Kuznetsov, G., Kumar, N., Wigle, T. J., Klaus, C. R., Allain, C. J., Raimondi, A., Waters, N. J., Smith, J. J., Porter-Scott, M., Chesworth, R., Moyer, M. P., … Keilhack, H. (2014). Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma. Molecular Cancer Therapeutics, 13(4), 842–854. https://doi.org/10.1158/1535-7163.MCT-13-0773

Chicago

Knutson, Sarah K, Satoshi Kawano, Yukinori Minoshima, Natalie M Warholic, Kuan-Chun Huang, Yonghong Xiao, Tadashi Kadowaki, et al. 2014. “Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma.” Molecular Cancer Therapeutics 13 (4): 842–54. doi:10.1158/1535-7163.MCT-13-0773.